These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 26882569)
1. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Yamaguchi K; Iglesias-Bartolomé R; Wang Z; Callejas-Valera JL; Amornphimoltham P; Molinolo AA; Cohen EE; Califano JA; Lippman SM; Luo J; Gutkind JS Oncotarget; 2016 Mar; 7(10):10696-709. PubMed ID: 26882569 [TBL] [Abstract][Full Text] [Related]
2. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740 [TBL] [Abstract][Full Text] [Related]
3. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087 [TBL] [Abstract][Full Text] [Related]
4. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines. Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609 [TBL] [Abstract][Full Text] [Related]
5. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975 [TBL] [Abstract][Full Text] [Related]
6. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin and trametinib: a rational combination for treatment of NSCLC. Sun CY; Li YZ; Cao D; Zhou YF; Zhang MY; Wang HY Int J Biol Sci; 2021; 17(12):3211-3223. PubMed ID: 34421360 [TBL] [Abstract][Full Text] [Related]
8. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
11. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985 [TBL] [Abstract][Full Text] [Related]
12. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159 [TBL] [Abstract][Full Text] [Related]
13. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells. Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279 [TBL] [Abstract][Full Text] [Related]